Form 4: Apellis Pharmaceuticals Director Gerald Chan Reports Stock Option Grant and Common Stock Acquisition
SEC Form 4 Filing
Director Gerald Chan reports acquisition of common stock and stock options in Apellis Pharmaceuticals.
Summary
- On January 1, 2025, Gerald Chan, a director of Apellis Pharmaceuticals, acquired 6,267 shares of common stock at $0 and was granted options to purchase 11,199 shares of common stock at an exercise price of $31.91.
- Following these transactions, Chan directly owns 17,705 shares of common stock and options for 11,199 shares.
- The stock options vest quarterly from the grant date and expire on December 31, 2032.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and options could be seen as a slightly positive signal.
Positives
- Director's acquisition of shares and options may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.
Stakeholder Impact
- Shareholders may view the director's stock acquisition as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Date of transaction: Acquisition of common stock and grant of stock options. |
| 01/03/2025 | Date of signature on the Form 4 filing. |
| 12/31/2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.